A multicentre phase II trial of intratumoral pIL-12 electroporation in advanced stage cutaneous and in transit malignant melanoma.

Trial Profile

A multicentre phase II trial of intratumoral pIL-12 electroporation in advanced stage cutaneous and in transit malignant melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Tavokinogene telsaplasmid (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors OncoSec Medical
  • Most Recent Events

    • 12 Oct 2017 According to an OncoSec media release, data will be presented at the 9th World Congress of Melanoma - A Joint Meeting with the Society for Melanoma Research.
    • 20 Apr 2016 Results (retrospective analysis, n = 34) assessing response to anti-PD-1/PD-L1 therapies post IT-pIL12-EP presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 17 Mar 2016 According to OncoSec media release, new clinical data will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top